HMB (Beta-Hydroxy Beta-Methylbutyrate)

What it is

Beta-hydroxy beta-methylbutyrate (HMB) is a metabolite produced endogenously during the catabolism of leucine, one of the three branched-chain amino acids. Approximately 5 percent of dietary leucine is converted to HMB via alpha-ketoisocaproic acid; the rest follows other metabolic routes. Because endogenous production from typical dietary leucine intake is small (estimated at around 0.3 grams per day in a person eating adequate protein) the theoretical rationale for supplementation is that pharmacological doses can achieve concentrations sufficient to exert measurable effects on muscle protein turnover that would not occur through diet alone.

HMB is proposed to act through two main mechanisms: inhibition of the ubiquitin-proteasome pathway, which is the primary intracellular system responsible for protein degradation, and activation of the mTOR signalling pathway, which stimulates muscle protein synthesis. These mechanisms are biologically plausible and supported by cell and animal studies. Whether they operate at clinically meaningful magnitudes in supplemented humans, particularly in those who are adequately nourished and not in a catabolic state, is the central question the clinical evidence must answer.

HMB supplements are available in two main forms: the calcium salt (HMB-Ca), which has been the predominant form used in clinical research, and the free acid form (HMB-FA), which has higher bioavailability and faster plasma clearance. Most of the published RCT evidence uses HMB-Ca at 3 grams per day, typically divided into two or three doses. The free acid form is more recent and, while pharmacokinetically distinct, the clinical trial base for it is considerably smaller. Standard dosing in research is 3 grams per day; doses up to 6 grams per day have been studied without apparent safety signals but without evidence of additional benefit.

What the evidence shows

The evidence for HMB divides clearly along population lines, and the split is important for interpreting the marketing claims that surround it.

In older adults and clinical populations with muscle wasting, the signal is directionally consistent but small. A 2025 meta-analysis in Frontiers in Nutrition (Ye et al.) examined 21 RCTs in adults over 50 (n=1935) based on heterogeneous trials of variable quality and found statistically significant effects on lean mass (weighted mean difference 0.28 kg, 95% CI 0.16 to 0.41 kg) and appendicular skeletal muscle mass. These effect sizes are small and may approach the lower bound of measurement sensitivity for DXA and bioelectrical impedance, raising genuine uncertainty about their clinical significance at the individual level. Importantly, increases in lean mass of this magnitude do not consistently translate into improvements in functional outcomes such as gait speed, falls risk, or independence. Subgroup analyses suggested effects were more pronounced with 3 grams per day over more than 12 weeks.

In trained younger adults, the evidence is largely negative for body composition and trivial for strength. A systematic review and meta-analysis by Jakubowski et al. (2020) examining 11 RCTs in adults aged 18 to 45 found no significant effects on fat-free mass, fat mass, or total body mass. Strength effects were trivial in trained individuals; a small lower-body strength signal was seen in untrained men in one earlier meta-analysis (Rowlands and Thomson, 2009), but this has not been consistently replicated. The HMB body composition effect in this population is, in the words of that review, inconsequential.

When HMB is added to resistance training in older adults, the incremental benefit over training alone is uncertain. A 2025 systematic review and meta-analysis (Paco-Fernandez et al., 10 RCTs, n=596) found only borderline significant improvements in handgrip strength (SMD 0.24, p=0.05) and moderate improvements in Short Physical Performance Battery scores (SMD 0.54, p=0.01) when comparing resistance training plus HMB against resistance training alone. No significant effects were found on lean mass, gait speed, fat mass, or body weight. Half of the included trials were rated at high risk of bias, which substantially limits confidence in the pooled estimates. Taken together, this suggests that in older adults already undertaking resistance training, HMB provides little additional benefit beyond training alone.

A persistent methodological problem across the HMB literature is the use of combination products. Many trials, particularly in clinical and older adult populations, administer HMB alongside amino acids such as arginine and glutamine, or as part of oral nutritional supplements containing protein, energy, and micronutrients. Where HMB is not the sole active ingredient, attributing observed effects specifically to HMB is not possible. Given the prevalence of combination products across the positive trial literature, the true independent effect of HMB may be smaller than pooled estimates suggest, and in some contexts may be negligible. The free acid form has higher bioavailability than the calcium salt form, but no clinical trials have demonstrated clear superiority in outcomes; pharmacokinetic advantage has not yet been shown to translate into greater clinical benefit.

Five questions

Does low HMB status cause harm? HMB is an endogenous metabolite and there is no defined deficiency state. Plasma HMB concentrations decline with age and are lower in older adults than younger adults, and lower in individuals consuming inadequate protein. Whether this age-related decline is causally related to muscle loss or is simply a consequence of reduced leucine turnover is not established.

Does supplementation prevent disease? HMB is not established as a disease-prevention agent. The most relevant clinical question is whether it slows or prevents sarcopenia, the age-related loss of muscle mass and function. The evidence suggests a small attenuation of muscle loss in supplemented older adults, but whether this translates to prevention of functional decline, falls, or other clinically meaningful outcomes has not been demonstrated in adequately powered trials.

Does it affect biomarkers? HMB supplementation is associated with small but statistically significant increases in lean mass in older adults across pooled analyses. Creatine kinase, a marker of muscle damage, has been examined in several trials with inconsistent results; the evidence that HMB meaningfully reduces exercise-induced muscle damage is not robust. Cholesterol-lowering effects have been reported in some early studies but are not consistently replicated and are not a supported primary use.

Does it help clinical populations? The most promising clinical application is in populations with significant muscle wasting. A systematic review by Prado et al. (Journal of Cachexia, Sarcopenia and Muscle, 2022) found that in higher-quality studies of cancer patients, HMB supplementation showed beneficial effects on muscle mass in four of four small studies and on muscle function in two of two small studies, though most used HMB in combination with arginine and glutamine rather than alone. These findings are based on small, heterogeneous studies and should be interpreted cautiously. Evidence in sarcopenic older adults, critically ill patients, and those with cancer cachexia is generally positive in direction but limited by small sample sizes, short durations, and frequent use of combination products.

Does it benefit healthy individuals? For healthy, well-nourished adults engaged in resistance training, the evidence does not support meaningful body composition or strength benefits beyond what training alone produces. This is particularly true for trained individuals. The case for HMB in this population rests primarily on marketing claims that the clinical evidence does not substantiate.

Individual variation

Training status is the most important moderating variable. Untrained individuals beginning a resistance training programme may experience small strength gains with HMB supplementation, particularly in lower-body strength, but these effects appear to diminish or disappear with training experience. Trained athletes consistently show trivial effects in meta-analyses. The proposed explanation is that HMB's anti-catabolic mechanism has most impact when muscle protein breakdown is high relative to synthesis, a state more characteristic of untrained beginners exposed to novel stress, or of catabolic clinical populations, than of conditioned athletes.

Age is the second major moderating variable. The evidence base is substantially stronger in adults over 50, and effects appear more pronounced in those over 65 with existing functional impairment or sarcopenia. This pattern is consistent with the anti-catabolic mechanism: older individuals have elevated baseline rates of muscle protein breakdown and blunted anabolic responses to both exercise and protein intake, making an anti-catabolic agent theoretically more useful.

Female-specific evidence is limited but not absent. Several trials in the older adult meta-analyses included women, and the overall lean mass signal appears to be present in mixed-sex samples. Dedicated female-specific analyses are not available. Given the relevance of sarcopenia to women's health (muscle mass loss accelerates around menopause and is associated with falls risk, metabolic health, and functional independence) the absence of sex-stratified analyses in most trials is a notable gap.

Protein intake may modulate response. HMB is a leucine metabolite, and adequate dietary protein provides the substrate from which HMB is naturally generated. Whether the effects seen in trials would hold in individuals already consuming high-protein diets is uncertain; some researchers have argued that the incremental benefit of HMB diminishes as protein intake increases, though this has not been formally tested. This raises the possibility that HMB offers little additional benefit in individuals already consuming adequate or high protein diets, which is relevant given that the populations most likely to self-supplement are often those already paying close attention to protein intake.

Testing and status assessment

There is no validated clinical test for HMB status. Plasma HMB concentrations can be measured but reference ranges have not been established for clinical use, and there is no evidence that testing plasma HMB would meaningfully guide supplementation decisions. Muscle mass assessment through DXA or bioelectrical impedance, and functional measures such as handgrip strength and gait speed, are the appropriate tools for monitoring sarcopenia and treatment response in clinical settings, but these are not HMB-specific.

Safety

Short-term studies suggest HMB is well tolerated at 3 grams per day. No significant adverse effects on liver enzyme function, kidney function, lipid profile, or immune markers have been reported in studies up to eight weeks. A study by Gallagher et al. found that 6 grams per day over eight weeks also showed no hepatic or renal safety signals in healthy individuals, though most high-dose safety data comes from short trials in younger adults rather than the older populations most likely to use HMB long term. Minor gastrointestinal symptoms including bloating, constipation, and occasional nausea have been reported in a small number of trial participants. Taking HMB with meals reduces gastrointestinal discomfort.

Long-term safety data beyond six months is limited, which is a relevant consideration given that the populations most likely to benefit (older adults managing sarcopenia) would be candidates for sustained use. No signals of harm have emerged from the available data, but the evidence base does not permit strong reassurance about very long-term effects.

Safety in pregnancy and lactation has not been studied. Use is not recommended in these groups in the absence of safety data.

No clinically significant drug interactions have been identified. HMB is not a stimulant, does not affect coagulation, and has no known interactions with common medication classes.

What can reasonably be concluded

HMB occupies a specific and relatively narrow evidence-supported niche: modest preservation of lean mass in older adults and in clinical populations with significant muscle wasting, particularly when used at 3 grams per day over periods exceeding 12 weeks. The effect sizes are small, and the frequent use of combination products in positive trials means that attribution to HMB specifically requires caution. In trained younger adults, the evidence for body composition or performance benefit is effectively absent.

The supplement is often marketed to athletes and gym users as a muscle-building agent. The clinical evidence does not support this framing for trained individuals. The populations where HMB appears most likely to offer meaningful benefit (older adults with sarcopenia, patients with cancer cachexia or other catabolic conditions, individuals with muscle wasting secondary to illness or bed rest) are not the populations typically targeted by sports supplement marketing, and they are the ones for whom clinical guidance rather than self-supplementation is most appropriate.

HMB is safe at standard doses and has a reasonable mechanistic rationale. The honest summary is that it is a modestly useful anti-catabolic agent for specific at-risk populations rather than a broadly effective muscle-building supplement. Whether these small effects justify routine supplementation depends heavily on context, and in many cases the same goals may be better served by adequate protein intake and progressive resistance training, both of which have substantially stronger evidence bases.

Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.